Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;25(45):2001735.
doi: 10.2807/1560-7917.ES.2020.25.45.2001735.

Epidemiological situation, laboratory capacity and preparedness for carbapenem-resistant Acinetobacter baumannii in Europe, 2019

Felix Lötsch  1 , Barbara Albiger  1 , Dominique L Monnet  1 , Marc J Struelens  1 , Harald Seifert  2   3 , Anke Kohlenberg  1 ; European Antimicrobial Resistance Genes Surveillance Network (EURGen-Net) carbapenem-resistant Acinetobacter baumannii capacity survey group  4 ; EURGen-Net carbapenem-resistant Acinetobacter baumannii capacity survey group
Collaborators, Affiliations

Epidemiological situation, laboratory capacity and preparedness for carbapenem-resistant Acinetobacter baumannii in Europe, 2019

Felix Lötsch et al. Euro Surveill. 2020 Nov.

Abstract

To update information on the epidemiological situation and national capacity for detection, surveillance and containment of carbapenem-resistant Acinetobacter baumannii (CRAb) in Europe, we performed a survey in 37 countries. Nine countries reported regional or inter-regional spread and seven an endemic situation. Laboratories with a reference function, surveillance systems, and a national containment plan for CRAb existed in 30, 23 and eight countries, respectively. A pan-European molecular survey would provide in-depth understanding of the CRAb epidemiology.

Keywords: Acinetobacter baumannii; Europe; Surveillance; Whole Genome Sequencing; carbapenem resistance; laboratory capacity.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: KLH and JT are members of PHE’s Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, which has received financial support for conference attendance, lectures, research projects, or contracted evaluations from numerous sources, including Accelerate Diagnostics, Achaogen Inc, Allecra Therapeutics, Amplex, AstraZeneca UK Ltd, AusDiagnostics, Basilea Pharmaceutica, Becton Dickinson Diagnostics, bioMérieux, Bio-Rad Laboratories, British Society for Antimicrobial Chemotherapy, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, the European Centre for Disease Prevention and Control, Food Standards Agency, GenePOC, GlaxoSmithKline Services Ltd, Helperby Therapeutics, Henry Stewart Talks, International Health Management Associates Ltd, Innovate UK, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe and Dohme, Meiji Seika Pharma Co Ltd, Mobidiag, Momentum Biosciences Ltd, Neem Biotech, NIHR, Nordic Pharma Ltd, Norgine Pharmaceuticals, Paratek, Rabiotics Rx, Rempex Pharmaceuticals Ltd, Roche, Rokitan Ltd, Smith and Nephew UK Ltd, Shionogi and Co Ltd, Tetraphase Pharmaceuticals, Trius Therapeutics, VenatoRx Pharmaceuticals, Wockhardt Ltd, and the World Health Organization.

Figures

Figure
Figure
Epidemiological situation of carbapenem-resistant Acinetobacter baumannii, assessment by national experts in European countries, 2019 (n = 37)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538-82. 10.1128/CMR.00058-07 - DOI - PMC - PubMed
    1. European Centre for Disease Prevention and Control (ECDC). Carbapenemase-producing bacteria in Europe - Interim results from the European survey on carbapenemase-producing Enterobacteriaceae (EuSCAPE) project 2013. Stockholm: ECDC; 2013. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publicat...
    1. Brolund A, Lagerqvist N, Byfors S, Struelens MJ, Monnet DL, Albiger B, et al. Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018. Euro Surveill. 2019;24(9):1900123. 10.2807/1560-7917.ES.2019.24.9.1900123 - DOI - PMC - PubMed
    1. Marí-Almirall M, Cosgaya C, Higgins PG, Van Assche A, Telli M, Huys G, et al. MALDI-TOF/MS identification of species from the Acinetobacter baumannii (Ab) group revisited: inclusion of the novel A. seifertii and A. dijkshoorniae species. Clin Microbiol Infect. 2017;23(3):210.e1-9. 10.1016/j.cmi.2016.11.020 - DOI - PubMed
    1. European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: Carbapenem-resistant Acinetobacter baumannii in healthcare settings. Stockholm: ECDC; 2016. Available from: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Pub...

MeSH terms

LinkOut - more resources